Vitamina C Tamponata 500 mg + Magnesio – 240 Capsule

Meta-analisi. Background Critically ill patients are frequently deficient in vitamin C. Given the significant mortality rates in the elderly population associated with COVID-19, we aimed to systematically review the literature and evaluate whether high-dose vitamin C can reduce COVID-19 mortality in this population. Methods Multiple data sources (PubMed, Web of Science, ScienceDirect, and medRxiv) were searched using the keywords "COVID-19" AND "vitamin C" up to November 2024. Randomized controlled trials (RCTs) involving COVID-19 patients with relevant data were collected. We used a random or fixed effects meta-analysis to calculate the pooling effect. Results Eight RCTs comprising 2,104 patients were ultimately included in the meta-analysis. The pooling effect (odds ratio [OR] 0.97[95% CI 0.80-1.18, P = 0.76) suggested no significant difference in mortality rates between patients treated with high-dose vitamin C and those who were not

Confronto dose

Non confrontata con la formula

Limiti

Pertinenza, popolazione, dosaggio, durata, rischi e conflitti di interesse richiedono verifica.

Studio randomizzato. Background Besides temperature management, there is currently no effective therapy to decrease the burden of post-cardiac arrest syndrome. The pleiotropic effects of vitamin C may improve clinical outcome. Purpose This trial investigated whether early administration of 3 g or 10 g intravenous vitamin C attenuated organ dysfunction post-cardiac arrest. Methods In this double-blind, multi-center, phase 2 trial, comatose adults resuscitated from shockable out-of-hospital cardiac arrest randomly received intravenously placebo, supplementary (3 g) or supraphysiological dose (10 g) vitamin C daily for 96 h. The primary endpoint was the 96 h change in the resuscitation-sequential organ failure assessment (R-SOFA) score. Secondary endpoints included neurological outcome, myocardial injury, vasopressor- and ventilator-free days, renal function, ICU-acquired weakness, delirium, length of ICU and hospital stay, and 28- and 180

Confronto dose

Non confrontata con la formula

Limiti

Pertinenza, popolazione, dosaggio, durata, rischi e conflitti di interesse richiedono verifica.

Studio randomizzato. Background and objectives High-dose intravenous vitamin C was associated with increased harm in adults with sepsis requiring vasopressors in the large international LOVIT trial. This population pharmacokinetic sub-study of LOVIT aimed to characterise the pharmacokinetics of vitamin C and explore associations with patient characteristics and outcomes. Methods Patients who enrolled in the LOVIT trial were randomized to receive 50 mg/kg vitamin C every 6 hours for 96 hours or placebo. Blood samples were collected on study Days 1, 3, and 7 for plasma vitamin C quantification. Population pharmacokinetic modeling was performed, with relevant patient and treatment-related factors tested as covariates. Internal validation was conducted using bootstrap resampling (n = 1000). Univariable and multivariable analyses explored associations between 28-day mortality and patient characteristics, as well as the relationship between v

Confronto dose

Non confrontata con la formula

Limiti

Pertinenza, popolazione, dosaggio, durata, rischi e conflitti di interesse richiedono verifica.

Studio randomizzato. Objectives Human T-lymphotropic virus type 1 (HTLV-1) infection is associated with progressive neurological impairment and reduced health-related quality of life (HRQoL). We evaluated longitudinal changes in HRQoL over 96 weeks in adults with HTLV-1 receiving dolutegravir compared with vitamin C. Methods This open-label, randomized controlled trial conducted in Brazil assigned participants to dolutegravir (50 mg/d) or vitamin C (500 mg/d). HRQoL was assessed using the RAND-36 questionnaire at baseline and week 96. Within-group changes were estimated using Cohen's d. Between-group comparisons for the Physical and Mental Component Summary scores (PCS and MCS) were performed using analysis of covariance adjusted for baseline values. Results Sixty-one participants completed follow-up (dolutegravir n = 34; vitamin C n = 27). The dolutegravir group showed improvements in physical functioning and pain domains. After adjust

Confronto dose

Non confrontata con la formula

Limiti

Pertinenza, popolazione, dosaggio, durata, rischi e conflitti di interesse richiedono verifica.

Studio clinico. Introduction Diabetes-related foot ulceration (DFU) is a serious complication, serving as a leading cause of amputation, disability, hospitalisation and a significant contributor to healthcare costs. Deficiencies in vitamin C and other micronutrients are common in DFU. Emerging evidence suggests vitamin C supplementation may enhance wound healing; however, high-quality randomised controlled trials are lacking. Therefore, the aim of this study is to investigate the efficacy of oral vitamin C supplementation (1 g/day) for 8 weeks on wound healing in people with DFU. Methods This is a multi-site, parallel group, randomised, placebo-controlled, double-blind trial. Eighty adults with DFU will be recruited and randomly assigned to either placebo or vitamin C supplementation (500 mg twice daily). Ulcer measurements will be obtained at baseline, 2, 4, 6 and 8 weeks with all other measures collected at baseline and 8 weeks. The p

Confronto dose

Non confrontata con la formula

Limiti

Pertinenza, popolazione, dosaggio, durata, rischi e conflitti di interesse richiedono verifica.

Studio randomizzato. Background Personalized antioxidant supplementation is promoted to optimize redox balance and inflammation profile. Objective To quantify the short-term effects of vitamin C supplementation on redox and inflammatory outcome measures and explore the potential for supplement response heterogeneity in participants with vitamin C inadequacy through aggregated sets of multi-cycle n-of-1 trials. Methods Eight healthy young males (age 25.56 ± 3.15 years, body mass 68.24 ± 9.70 kg) completed four supplementation (vitamin C 1g) and four placebo trials administered on repeated occasions in randomized sequences following a 1-month run-in period. Vitamin C, F 2 -isoprostanes, interleukin-6, and tumor necrosis factor-α were assessed as primary outcomes. Separate within-participant linear mixed-effects modelling and meta-analytic models estimated replicate-averaged treatment effects and person-by-treatment response variation to v

Confronto dose

Non confrontata con la formula

Limiti

Pertinenza, popolazione, dosaggio, durata, rischi e conflitti di interesse richiedono verifica.